Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for BioForce Nanosciences Holdings's Equity-to-Asset or its related term are showing as below:
BFNH'
s Equity-to-Asset Range Over the Past 10 Years
Min: -2302 Med: -20.93 Max: 1
Current: 0.96
During the past 13 years, the highest Equity to Asset Ratio of BioForce Nanosciences Holdings was 1.00. The lowest was -2302.00. And the median was -20.93.
BFNH's Equity-to-Asset is ranked better than 98.25% of 1996
companies
in the Consumer Packaged Goods industry
Industry Median: 0.55
vs BFNH: 0.96
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
BioForce Nanosciences Holdings Equity-to-Asset Related Terms
BioForce Nanosciences Holdings Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BFNH vs BHST, LSF, HAIN: Equity-to-Asset Comparison
For the Packaged Foods subindustry, BioForce Nanosciences Holdings's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioForce Nanosciences Holdings Equity-to-Asset vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, BioForce Nanosciences Holdings's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where BioForce Nanosciences Holdings's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioForce Nanosciences Holdings (BFNH) has a Equity-to-Asset of 0.96 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on BioForce Nanosciences Holdings and its competitors. According to the industry distribution chart, BioForce Nanosciences Holdings ranks #35 out of 1996 companies in the Consumer Packaged Goods industry, placing it in the top 1.8%.
Is BioForce Nanosciences Holdings' Equity-to-Asset too high?
BioForce Nanosciences Holdings' current Equity-to-Asset is 0.96. The Consumer Packaged Goods industry median Equity-to-Asset is 0.55. BioForce Nanosciences Holdings' value of 0.96 is 74.5% above this industry median. Based on the distribution chart, BioForce Nanosciences Holdings ranks #35 out of 1996 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, BioForce Nanosciences Holdings has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does BioForce Nanosciences Holdings' Equity-to-Asset compare to BHST and LSF?
According to the Consumer Packaged Goods industry distribution chart, BioForce Nanosciences Holdings ranks #35 out of 1996 companies for Equity-to-Asset. This places BioForce Nanosciences Holdings in the top 2% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.55. BioForce Nanosciences Holdings' value of 0.96 is 74.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Consumer Packaged Goods company?
The median Equity-to-Asset among Consumer Packaged Goods companies is 0.55, based on 1,996 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioForce Nanosciences Holdings's current Equity-to-Asset of 0.96 is 74.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on BioForce Nanosciences Holdings and its competitors. For the Consumer Packaged Goods industry, the median Equity-to-Asset is 0.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioForce Nanosciences Holdings's current Equity-to-Asset is 0.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioForce Nanosciences Holdings stock overvalued right now?
BioForce Nanosciences Holdings (BFNH) has a current Equity-to-Asset of 0.96. The current Equity-to-Asset is 0.96 and 74.5% above the Consumer Packaged Goods industry median of 0.55. BioForce Nanosciences Holdings' overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For BioForce Nanosciences Holdings (BFNH), the current Equity-to-Asset is 0.96 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BioForce Nanosciences Holdings Inc is a provider of natural vitamins, minerals, and other nutritional supplements, powders, and beverages. It markets its products through social media and telemarketing. BioForce currently markets its products through social media and telemarketing. Nutrition retailers, grocery stores, retail pharmacies, and online stores, like Amazon, will be important channels for the Company's Eclipse product-lines.
34GF Score
Get the complete analysis for BFNH
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BFNH has been successfully added to your 
